In fact, the presence of circulating tumor antigen-specific CD8 T cells alone is not sufficient to control tumor growth (141, 143), highlighting the potential therapeutic benefit of targeting tissue-resident lymphocytes. The gene discussed is CD8A; the disease is neoplasm.